Basilea Pharmaceutica (BPMUF) Upgraded by Zacks Investment Research to “Buy”
Zacks Investment Research upgraded shares of Basilea Pharmaceutica (OTCMKTS:BPMUF) from a hold rating to a buy rating in a research report released on Monday. Zacks Investment Research currently has $69.00 price objective on the stock.
According to Zacks, “BASILEA PHARMACEUTICA LTD. is headquartered in Basel, Switzerland, and listed on the SWX Swiss Exchange. Basilea’s integrated research and development operations are currently focused on new antibacterial and antifungal agents to fight drug resistance and on the development of dermatology drugs. Basilea’s products are targeted to satisfy high medical and patient needs in the hospital and specialty care setting. The company owns a diversified portfolio including two drugs under regulatory review (ceftobiprole and alitretinoin) and one phase-III investigational drug (isavuconazole). The company is currently building its sales and marketing organization to commercialize alitretinoin and to co-promote ceftobiprole in North America and major European countries, subject to approval. “
Separately, Cantor Fitzgerald reaffirmed an overweight rating on shares of Basilea Pharmaceutica in a research note on Monday, September 10th.
About Basilea Pharmaceutica
Basilea Pharmaceutica AG, together with its subsidiaries, operates as an integrated biopharmaceutical company. The company focuses on the discovery, development, and commercialization of pharmaceutical products in the therapeutic areas of bacterial and fungal infections, and oncology. It offers isavuconazole, an intravenous and oral antifungal drug for the treatment of invasive mold infections under the name of CRESEMBA worldwide.
Featured Article: Are analyst ratings accurate?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.